<DOC>
	<DOC>NCT00753740</DOC>
	<brief_summary>This study will assess the effect of IT-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.</brief_summary>
	<brief_title>Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Key Women between the age of 18 and 78, inclusive; Evidence of platinumsensitive ovarian cancer following the patient's primary treatment(&gt;= 6 months); Received a 2nd line platinumbased chemotherapy regimen (46 cycles) without evidence of progression; May have measurable or unmeasurable disease; ECOG 0 or 1; Ability to understand and the willingness to sign a written informed consent document. Key Women who are pregnant or lactating; Prior treatment with a topoisomerase inhibitor; Patients with unacceptable organ and/or hematologic reserve at screening; Urine protein of &gt; 500 mg/day or active nephropathy; Electrocardiogram (ECG) with evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator; History of pancreatitis within the last 12 months; Patients treated with previous high dose chemotherapy or stem cell transplant within the last 5 years; Use of any investigational agents within 4 weeks of study enrollment; Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, psychiatric illness or other comorbidity that presents a risk to the patient as determined by the investigator.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Solid Malignancies</keyword>
</DOC>